Critical Appraisal of the Views of Healthcare Professionals with Respect to Pharmacogenomics and Personalized Medicine in Greece

Mai, Yuan; Mitropoulou, Christina; Papadopoulou, Xanthi E.; Vozikis, Athanassios; Cooper, David Neil; Schaik, Ron H.N. van; Patrinos, George P.

doi:10.2217/pme.13.92

Cited by 48 publications

(51 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). These data are comparable to recent surveys in Greece [4,8] and the USA [2], indicating that more in-depth pharmacogenomics education should be implemented so that all practicing physicians feel more confident to exploit the benefits of pharmacogenomics in optimizing drug treatment modalities. From the above, it is evident that physicians should receive some basic pharmacogenomics education during their undergraduate and/or graduate training.…”

Section: Discussionsupporting

confidence: 82%

“…Also, the study sample of our survey was rather small compared to previous studies. However, one should also bear in mind that although this survey was a university-wide rather than a nation-wide survey, which included a smaller respondents sample, the resulting data were comparable to other previously conducted studies [2,4]. …”

Section: Discussionsupporting

confidence: 67%

“…In another US-based study of 597 primary care physicians, although the majority of respondents had heard of and appreciated the benefits of pharmacogenomic testing, only 13% of them indicated that they felt comfortable ordering such tests, while 22% reported that they had not received any education in pharmacogenomics [3]. Similar results were also obtained from a recent study involving both physicians and pharmacists in Greece, who admitted that they did not feel sufficiently competent to explain the results of pharmacogenomic tests to their clients [4]. Surprisingly, results from a study involving 516 clinical geneticists and genetic counselors, all of whom have received some form of pharmacogenomics education, showed that only 28% of counselors and 58% of clinical geneticists felt well informed enough to order tests or counsel their patients over pharmacogenomic test results [5].…”

Section: Introductionmentioning

confidence: 68%

See 2 more Smart Citations

Assessment of the Pharmacogenomics Educational Environment in Southeast Europe

Pisanu

Tsermpini

Mavroidi

et al. 2014

Public Health Genomics

View full text Add to dashboard Cite

Background/Aims: Pharmacogenomics aims to use the information derived from an individual's genomic profile in the context of individualizing medical treatment modalities. However, currently, pharmacogenomics education is not uniformly provided to health care professionals. This study investigates the status of pharmacogenomics education in Southeast Europe. Methods: University websites served as information sources in order to investigate the discrepancies in pharmacogenomics education in Southeast Europe. In parallel, a survey was conducted at the University of Cagliari (Italy) to test pharmacogenomics knowledge and understanding among specialists, residents and undergraduate students. Results: Our study shows that pharmacogenomics knowledge is not uniformly spread in universities in Southeast Europe and provides the basis for the harmonization of pharmacogenomics education that would directly impact on a smoother integration of pharmacogenomics into mainstream medical practice. Also, a considerable gap in pharmacogenomics education was obvious between the group of specialists and the groups of residents and undergraduate students. Conclusions: Pharmacogenomics education as well as the continuous enrichment of pharmacogenomics knowledge for health care professionals are fundamental approaches toward personalized medicine. Ideally, pharmacogenomics should be taught as a stand-alone course or at least in the context of genetics courses that already exist in universities in Southeast Europe.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 67%

Section: Introductionmentioning

confidence: 68%

See 1 more Smart Citation

Assessment of the Pharmacogenomics Educational Environment in Southeast Europe

Pisanu

Tsermpini

Mavroidi

et al. 2014

Public Health Genomics

View full text Add to dashboard Cite

show abstract

“…Such studies would facilitate adopting certain policies and performing the necessary steps that would expedite integration of genomics into healthcare. These studies, conducted in various countries in Europe and the US [3,4,5,6,7], have shown that the level of the general public's awareness of genomic medicine and its impact on society is often rather low, which constitutes a major barrier to expediting the implementation of genomic medicine. In addition, the lack of proper mapping of the opinions of various stakeholders leads to an inadequately regulated environment in the field.…”

Section: Introductionmentioning

confidence: 99%

Stakeholder Analysis in Pharmacogenomics and Genomic Medicine in Greece

Mitropoulou

Mai

Schaik

et al. 2014

Public Health Genomics

Self Cite

View full text Add to dashboard Cite

Background: The pace of discoveries and advances in genomic research is not reflected in the pace of their translation and incorporation into day-to-day clinical medicine to individualize healthcare decision-making processes. One of the main obstacles is the poor understanding of the policies and the key stakeholders involved in these translation processes. Methods: We used the computerized version of the PolicyMaker political mapping tool to collect and organize important information about the pharmacogenomics and genomic medicine policy environment, serving as a database for assessments of the policy's content, the major players, their power and policy positions, their interests, and networks and coalitions that interconnect them. Results and Conclusions: Our findings indicate that the genomic medicine policy environment in Greece seems to be rather positive, as the vast majority of the stakeholders express their medium to high support in the initially set goals of genomic medicine policy environment. The Ministry of Health and public healthcare insurance funds seem to oppose it, most likely due to financial constrains. These findings would contribute in selecting and implementing policy measures that will expedite the adoption of genomics into conventional medical interventions.

show abstract

“…We, therefore, argue that the bottleneck for the implementation of pharmacogenomics does not lie in the lack of evidence demonstrating clinical utility but rather lies in the unfamiliarity and lack of genetics knowledge among physicians and other health-care providers. [22][23][24] This bottleneck will be addressed within the U-PGx consortium through an e-learning tool, which aims to increase physician knowledge and know-how with pharmacogenomics.…”

mentioning

confidence: 99%